olfactomedin like 1Genealiases: MVAL564 · ONT2 · UNQ564
Q-omics provides the consensus-scored OLFML1 profile across patient tissues and cancer cell-line models. OLFML1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, OLFML1 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, OLFML1 protein abundance shows 31,287 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, and LUAD as cancer lineages where OLFML1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OLFML1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OLFML1 survival associations across molecular data types. OLFML1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OLFML1 RNA expression–survival associations across cancer types. High OLFML1 expression shows unfavorable associations in KIRP and LGG, but favorable associations in LUAD, HNSC, UCEC and MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for OLFML1 RNA expression.
This table summarizes OLFML1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for OLFML1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OLFML1 shows lower tumor expression in LUAD, KICH, COAD, BLCA and THCA and higher tumor expression in KIRC. The LUAD box plot shows higher OLFML1 RNA expression in normal versus tumor tissue (log2 FC = −1.458, t-test p < 0.001).
This table shows molecular features associated with OLFML1 in patient tissues and cancer cell lines. In patient samples, OLFML1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OLFML1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
